Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ritivixibat by Ipsen for Primary Sclerosing Cholangitis: Likelihood of Approval
Ritivixibat is under clinical development by Ipsen and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase...